Date: Thursday, 19 November 2026
Time: 08:00 PST | 11:00 EST | 16:00 GMT
Topic: Accelerating Molecular Insights in Pediatric Brain Tumor Diagnosis
In the high-stakes environment of pediatric oncology, time is the most precious resource. For children diagnosed with brain tumors, the current diagnostic journey—often characterized by invasive biopsies, fragmented testing, and weeks of anxious waiting—is ripe for transformation. A groundbreaking upcoming webinar, hosted in association with Oxford Nanopore Technologies, is set to unveil how long-read sequencing (LRS) is poised to rewrite the standard of care for pediatric neuro-oncology.
Main Facts: A New Frontier in Molecular Diagnostics
The traditional diagnostic pipeline for pediatric brain tumors is inherently inefficient. Clinicians often rely on a patchwork of tests—ranging from immunohistochemistry and chromosomal microarrays to next-generation sequencing panels—to build a complete molecular profile. This process consumes significant amounts of tumor tissue, a major challenge when dealing with small pediatric samples, and keeps families in a state of diagnostic limbo for weeks.
Long-read sequencing (LRS) is emerging as a paradigm-shifting alternative. Unlike traditional short-read platforms that "stitch" together small fragments of DNA, LRS reads longer strands of genetic material, allowing for a more comprehensive view of complex structural variations and epigenetic markers. Most notably, the technology’s ability to perform real-time methylation analysis could potentially allow for tumor classification within minutes of the sequencing run beginning, providing actionable data at a speed previously thought impossible.
Chronology: The Evolution of Genomic Diagnostics
To understand the magnitude of this innovation, one must look at the progression of oncology diagnostics:

- Pre-2010s: Diagnosis was primarily histological, relying on pathologists’ visual inspection of tumor morphology.
- 2015–2020: The rise of short-read next-generation sequencing (NGS) enabled the identification of specific gene mutations, though it struggled with structural variants and repetitive genomic regions.
- 2021–2025: The integration of DNA methylation profiling became a gold standard for pediatric brain tumor classification, yet it remained a time-intensive, centralized laboratory process.
- Late 2026 (The Current Horizon): The transition toward real-time, long-read nanopore sequencing marks the beginning of "point-of-care" molecular pathology. The research to be discussed in the upcoming webinar represents the latest maturation of this technology, shifting from proof-of-concept to clinical utility.
Supporting Data: Validating the Paradigm Shift
The upcoming presentation features Min Seon Park, a researcher from the University of Washington’s Institute of Public Health Genetics. Park’s recent study serves as a critical validation point for the clinical application of nanopore technology.
The research utilized Oxford Nanopore sequencing to profile both genetic variants and DNA methylation patterns in a cohort of pediatric brain tumor samples. The results were striking: the study demonstrated high concordance between whole-genome and targeted LRS results and the existing standard clinical testing protocols.
By achieving this level of accuracy with less sample material, the study addresses the "tissue scarcity" dilemma. For pediatric patients, whose tumors are often located in delicate, difficult-to-reach areas of the brain, the ability to extract a comprehensive molecular report from a minimal biopsy is not just a technological win—it is a patient-safety imperative.
Official Perspectives: The Experts Leading the Charge
The webinar will feature two prominent voices in the field, each offering a unique perspective on the intersection of technology and patient care.
Min Seon Park: Bridging Genetics and Patient Care
Min Seon Park is a PhD student at the University of Washington whose work centers on leveraging LRS to identify disease-causing variants and clarify the relationship between genotype and phenotype. Park’s unique background as a certified genetic counselor provides her with a perspective that is rare in pure genomic research. She is deeply committed to ensuring that technological advancements in the lab translate directly into more effective, compassionate, and patient-centered clinical care.

Ellie Juarez: Scaling Innovation
Eleonora (Ellie) Juarez, Director of the Oncology Market Segment at Oxford Nanopore Technologies, brings a doctorate in molecular and medical genetics to the discussion. With a distinguished career spanning leadership roles at Twinstrand Biosciences, Integrated DNA Technologies (IDT), and Twist Bioscience, Juarez is at the forefront of the commercial and strategic deployment of these tools. Her expertise ensures that the webinar will not only cover the science but also the practical hurdles of integrating such high-tech solutions into routine clinical workflows.
Implications for the Future of Neuro-Oncology
The implications of this shift are profound, affecting every stakeholder in the pediatric oncology ecosystem.
For Clinicians
The most immediate benefit is the reduction in "Time to Action." In pediatric neuro-oncology, therapeutic decisions—such as the initiation of targeted therapies or the refinement of surgical approaches—are contingent upon molecular diagnosis. Reducing the diagnostic wait time from weeks to potentially days (or even hours) allows clinicians to intervene while the tumor is in its most treatable stage.
For Families
Beyond the biological data, there is the human element. The waiting period for test results is often described by parents as the most difficult aspect of the diagnostic journey. By streamlining this process, the medical community can reduce the psychological burden on families, providing clarity and direction when they need it most.
For the Healthcare System
The efficiency gains are equally significant. By utilizing a single platform to perform multiple functions (variant calling and methylation profiling), hospitals can reduce the number of individual tests ordered, streamline lab resources, and lower the costs associated with the diagnostic odyssey.

Conclusion: A Call to Action
The integration of nanopore sequencing into pediatric brain tumor research is not merely an incremental improvement; it is a fundamental reconfiguration of how we approach cancer diagnostics. By providing deep, multi-omic insights from minimal tissue, this technology offers a vision of the future where the diagnostic journey is shorter, more precise, and more accessible.
The upcoming webinar on November 19, 2026, promises to be a critical touchpoint for researchers, clinicians, and genetic counselors interested in the future of oncology. As the field moves toward real-time molecular diagnostics, the collaboration between experts like Min Seon Park and industry leaders like Oxford Nanopore Technologies remains essential to ensuring that these powerful tools reach the patients who need them most.
Who Should Attend?
This session is tailored for:
- Pediatric Neuro-oncologists looking to integrate rapid molecular testing into their practice.
- Molecular Pathologists interested in the technical capabilities of long-read methylation classifiers.
- Genetic Counselors seeking to better understand the nuances of the latest diagnostic workflows.
- Translational Researchers focused on genomic medicine and oncology assay development.
Register Now to secure your place in this conversation, as the community prepares to embrace a new era of precision in pediatric brain tumor care. The future of oncology is being written in long reads, and the path forward is clearer than ever.
